Determine trial treatment arm 1: A phase 2/3 trial of alectinib in people with ALK positive lymphomas

This trial is testing the medication alectinib in people with anaplastic lymphoma kinase (ALK) positive lymphomas.

You can share the following ClinicalTrials.gov Identifier with your medical team so they can find out more about the trial: NCT05770037
 

Trial aim and background  

The medication alectinib is approved in the treatment of people with certain lung cancers with the particular mutation ALK in their cancer. This mutation is found in other cancers including certain lymphomas and so this study aims to see if alectinib is effective in there as well. 

It is part of a trial programme called Determine which will look at other anti-cancer drugs in the same way.

Participants in the trial will receive alectinib until their disease progresses, they develop toxicity or they withdraw consent. The effectiveness of alectinib will be assessed by cancer response, and absence of progression.

Who can enter

People of any age with an ALK positive lymphoma may be eligible for this trial.

Locations

Recruitment is taking place in the following UK locations:

  • Belfast City Hospital, Belfast
  • University Hospital Birmingham, Birmingham
  • Birmingham Children's Hospital, Birmingham
  • Bristol Royal Hospital for Children, Bristol
  • Bristol Haematology and Oncology Centre, Bristol
  • Addenbrooke's Hospital, Cambridge
  • Velindre Cancer Centre, Cardiff
  • Western General Hospital, Edinburgh
  • The Beatson Hospital, Glasgow
  • Royal Hospital for Children Glasgow, Glasgow
  • Leeds General Infirmary, Leeds
  • Leicester Royal Infirmary, Leicester
  • Alder Hey Hospital, Liverpool
  • The Royal Marsden Hospital, London
  • University College London Hospital, London
  • Guy's Hospital, London
  • Great Ormond Street Hospital, London
  • Royal Manchester Children's Hospital, Manchester
  • The Christie Hospital, Manchester
  • Great North Children's Hospital, Newcastle
  • Freeman Hospital, Newcastle
  • Churchill Hospital, Oxford
  • John Radcliffe Hospital, Oxford
  • Weston Park Hospital, Sheffield
  • Southampton General Hospital, Southampton
  • Clatterbridge Cancer Centre, Wirral

Further information 

More information about what treatments are involved, the criteria you must meet in order to take part in the trial and where this trial is taking place are available at: https://clinicaltrials.gov/ct2/show/NCT05770037

Lymphoma Action are not able to refer people to specific trials. If you are interested in taking part in this trial we recommend that you print the trial summary and discuss it with your medical team. They can advise you on whether you might be eligible for the trial and how you can take part based on your individual circumstances.